ChemoCentryx (ChemoCentryx) Institutional Ownership : 67.72% (As of Apr. 25, 2024)

View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ChemoCentryx's institutional ownership is 67.72%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ChemoCentryx's Insider Ownership is 4.70%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ChemoCentryx's Float Percentage Of Total Shares Outstanding is 95.53%.

ChemoCentryx Institutional Ownership Historical Data

The historical data trend for ChemoCentryx's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx Institutional Ownership Chart

ChemoCentryx Historical Data

The historical data trend for ChemoCentryx can be seen below:

	2021-12-31	2022-01-31	2022-02-28	2022-03-31	2022-04-30	2022-05-31	2022-06-30	2022-07-31	2022-08-31	2022-09-30
Institutional Ownership	62.13	62.32	62.45	63.51	63.25	63.81	70.72	69.50	69.80	67.72

ChemoCentryx Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

ChemoCentryx (ChemoCentryx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070

Website

https://www.chemocentryx.com

ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Executives

Susan M Kanaya	officer: SVP Finance, CFO & Secretary	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall	director, 10 percent owner, officer: President, CEO and Director	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau	officer: SVP, Finance & Acctg Officer	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd	10 percent owner	RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt	officer: EVP, Chief Operating Officer	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards	director	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel	officer: CBO and Treasurer	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan	officer: Principal Acctg Officer	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh	officer: SVP, Research	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd.	10 percent owner	UNTERMATTWEG 8, BERNE V8 CH-3027